89 related articles for article (PubMed ID: 21141268)
1. [Prevalence in adults of attention deficit hyperactivity disorder using the medical records of primary care].
Aragonès E; Lluís Piñol J; Ramos-Quiroga JA; López-Cortacans G; Caballero A; Bosch R
Rev Esp Salud Publica; 2010; 84(4):417-22. PubMed ID: 21141268
[TBL] [Abstract][Full Text] [Related]
2. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders.
Pérez de Los Cobos J; Siñol N; Puerta C; Cantillano V; López Zurita C; Trujols J
Psychiatry Res; 2011 Jan; 185(1-2):205-10. PubMed ID: 20537723
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care.
Faraone SV; Spencer TJ; Montano CB; Biederman J
Arch Intern Med; 2004 Jun; 164(11):1221-6. PubMed ID: 15197048
[TBL] [Abstract][Full Text] [Related]
4. Adult ADHD: prevalence of diagnosis in a US population with employer health insurance.
Montejano L; Sasané R; Hodgkins P; Russo L; Huse D
Curr Med Res Opin; 2011; 27 Suppl 2():5-11. PubMed ID: 21973227
[TBL] [Abstract][Full Text] [Related]
5. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
6. Review of medication adherence in children and adults with ADHD.
Adler LD; Nierenberg AA
Postgrad Med; 2010 Jan; 122(1):184-91. PubMed ID: 20107302
[TBL] [Abstract][Full Text] [Related]
7. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants.
Nierenberg AA; Miyahara S; Spencer T; Wisniewski SR; Otto MW; Simon N; Pollack MH; Ostacher MJ; Yan L; Siegel R; Sachs GS;
Biol Psychiatry; 2005 Jun; 57(11):1467-73. PubMed ID: 15950022
[TBL] [Abstract][Full Text] [Related]
8. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of epilepsy and attention-deficit hyperactivity (ADHD) disorder: a population-based study.
Cohen R; Senecky Y; Shuper A; Inbar D; Chodick G; Shalev V; Raz R
J Child Neurol; 2013 Jan; 28(1):120-3. PubMed ID: 22550087
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
11. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.
Fogelman Y; Kahan E
Isr Med Assoc J; 2001 Dec; 3(12):925-7. PubMed ID: 11794916
[TBL] [Abstract][Full Text] [Related]
12. [Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention deficit hyperactivity disorder].
Criado Alvarez JJ; Romo Barrientos C
Rev Neurol; 2003 Nov 1-15; 37(9):806-10. PubMed ID: 14606045
[TBL] [Abstract][Full Text] [Related]
13. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.
Sankaranarayanan J; Puumala SE; Kratochvil CJ
Curr Med Res Opin; 2006 Aug; 22(8):1475-91. PubMed ID: 16870073
[TBL] [Abstract][Full Text] [Related]
15. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
16. Seasonality of mood disorders in adults with lifetime attention-deficit/hyperactivity disorder (ADHD).
Amons PJ; Kooij JJ; Haffmans PM; Hoffman TO; Hoencamp E
J Affect Disord; 2006 Apr; 91(2-3):251-5. PubMed ID: 16458365
[TBL] [Abstract][Full Text] [Related]
17. Screening and imputed prevalence of ADHD in adult patients with comorbid substance use disorder at a residential treatment facility.
Adler LA; Guida F; Irons S; Rotrosen J; O'Donnell K
Postgrad Med; 2009 Sep; 121(5):7-10. PubMed ID: 19820269
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
19. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Birnbaum HG; Kessler RC; Lowe SW; Secnik K; Greenberg PE; Leong SA; Swensen AR
Curr Med Res Opin; 2005 Feb; 21(2):195-206. PubMed ID: 15801990
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective.
Babcock T; Ornstein CS
Postgrad Med; 2009 May; 121(3):73-82. PubMed ID: 19491543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
